Pulse Biosciences (PLSE) to Announce Earnings on Thursday

Pulse Biosciences (NASDAQ:PLSE) will likely be issuing its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect the company to post earnings of ($0.2933) per share and revenue of $0.5330 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Thursday, August 6, 2026 at 4:30 PM ET.

Pulse Biosciences (NASDAQ:PLSE) last posted its earnings results on Monday, May 4th. The company reported ($0.27) EPS for the quarter, topping the consensus estimate of ($0.32) by $0.05. The business had revenue of $0.40 million for the quarter, compared to the consensus estimate of $0.25 million. On average, analysts expect Pulse Biosciences to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Pulse Biosciences Stock Up 0.6%

PLSE stock traded up $0.23 during mid-day trading on Tuesday, reaching $37.96. 84,211 shares of the company traded hands, compared to its average volume of 338,381. The stock has a market cap of $2.63 billion, a price-to-earnings ratio of -34.40 and a beta of 1.61. Pulse Biosciences has a fifty-two week low of $12.56 and a fifty-two week high of $38.90. The firm’s 50 day moving average price is $27.89 and its 200 day moving average price is $23.01.

Insider Activity at Pulse Biosciences

In other Pulse Biosciences news, Director Robert W. Duggan acquired 660,233 shares of the stock in a transaction dated Monday, May 11th. The stock was purchased at an average cost of $19.69 per share, for a total transaction of $12,999,987.77. Following the acquisition, the director owned 48,211,433 shares in the company, valued at $949,283,115.77. The trade was a 1.39% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Paul A. Laviolette purchased 15,000 shares of the business’s stock in a transaction on Monday, May 11th. The shares were acquired at an average price of $19.69 per share, with a total value of $295,350.00. Following the completion of the transaction, the chief executive officer owned 15,000 shares of the company’s stock, valued at approximately $295,350. This trade represents a ∞ increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Company insiders own 74.00% of the company’s stock.

Hedge Funds Weigh In On Pulse Biosciences

A number of hedge funds have recently modified their holdings of the company. BNP Paribas Financial Markets lifted its holdings in Pulse Biosciences by 63.6% in the 2nd quarter. BNP Paribas Financial Markets now owns 1,749 shares of the company’s stock worth $26,000 after buying an additional 680 shares during the period. Tower Research Capital LLC TRC lifted its stake in Pulse Biosciences by 275.0% in the second quarter. Tower Research Capital LLC TRC now owns 2,940 shares of the company’s stock worth $44,000 after acquiring an additional 2,156 shares during the period. Russell Investments Group Ltd. boosted its holdings in Pulse Biosciences by 13.8% in the fourth quarter. Russell Investments Group Ltd. now owns 5,106 shares of the company’s stock valued at $70,000 after acquiring an additional 619 shares in the last quarter. The Manufacturers Life Insurance Company purchased a new position in Pulse Biosciences during the 2nd quarter valued at $158,000. Finally, Brevan Howard Capital Management LP purchased a new position in Pulse Biosciences during the 2nd quarter valued at $215,000. Hedge funds and other institutional investors own 76.95% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on the company. Oppenheimer restated an “outperform” rating on shares of Pulse Biosciences in a research note on Tuesday, July 28th. Canaccord Genuity Group began coverage on shares of Pulse Biosciences in a report on Thursday, June 4th. They set a “buy” rating and a $32.00 price target on the stock. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Pulse Biosciences in a research note on Friday, July 17th. Three investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Pulse Biosciences presently has a consensus rating of “Moderate Buy” and an average target price of $32.33.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc is a clinical-stage bioelectric medicine company that develops and commercializes medical devices based on its proprietary Tissue NanoPoration (TNP) platform. The company’s core technology, NanoPulse Stimulation (NPS), delivers ultrashort, high-voltage electric pulses to targeted tissue, triggering cellular responses without the thermal damage associated with traditional energy-based devices. Pulse Biosciences focuses on applications in dermatology and aesthetic medicine, where controlled ablation of unwanted lesions is critical.

The company’s flagship product, the CellFX® System, is designed to treat a range of benign and malignant skin lesions, including seborrheic keratosis, non-melanoma skin cancers, and various epidermal and dermal lesions.